The Ubiquitin Carboxyl Terminal Hydrolase 30 pipeline drugs market research report outlays comprehensive information on the Ubiquitin Carboxyl Terminal Hydrolase 30 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ubiquitin Carboxyl Terminal Hydrolase 30 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, Genito Urinary System, and Undisclosed which include the indications Congestive Heart Failure (Heart Failure), Parkinson’s Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), and Unspecified. It also reviews key players involved in Ubiquitin Carboxyl Terminal Hydrolase 30 targeted therapeutics development with respective active and dormant or discontinued products.
The Ubiquitin Carboxyl Terminal Hydrolase 30 pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 3, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Ubiquitin Carboxyl Terminal Hydrolase 30 overview
Ubiquitin Carboxyl-Terminal Hydrolase 30 (UCHL30), also known as Ubiquitin-Specific Peptidase 30 (USP30), is a deubiquitinating enzyme that plays a critical role in the regulation of mitochondrial homeostasis. The primary function of UCHL30 is to remove ubiquitin molecules from specific protein substrates, thereby modulating various cellular processes. One of the notable functions of UCHL30 is its involvement in the maintenance of mitochondrial quality control. It is primarily localized to the outer mitochondrial membrane and participates in the regulation of mitophagy—a selective form of autophagy that targets damaged or dysfunctional mitochondria for degradation. By deubiquitinating specific substrates involved in mitophagy, UCHL30 influences the clearance of impaired mitochondria, contributing to overall cellular health. The interplay between ubiquitination and deubiquitination, orchestrated by enzymes like UCHL30, is crucial for the dynamic regulation of mitochondrial function and turnover. Dysregulation of these processes has been implicated in various neurodegenerative diseases and metabolic disorders.
For a complete picture of Ubiquitin Carboxyl Terminal Hydrolase 30’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
